在阿尔茨海默病中,ApoE,睡眠以及Aβ和tau病理之间的联系
Katherine R Sadleir1, Robert Vassar1,2
1Davee Department of Neurology and.
The Journal of clinical investigation
|July 18, 2023
概括
睡眠障碍加剧了阿尔茨海默病 (AD) 病理,特别是在具有APOE4基因的个体中. 这种遗传因素加剧了粉样蛋白和陶的积累,造成睡眠不良和AD风险增加的循环.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 睡眠医学 睡眠医学
背景情况:
- 睡眠障碍是阿尔茨海默病 (AD) 的环境风险因素.
- 在阿波利波蛋白E4 (APOEε4) 的等位基因是AD的一个显著的遗传风险因素.
- 在AD病变发生过程中,睡眠障碍与APOEε4之间的相互作用需要进一步研究.
研究的目的:
- 在APOEε4.4.的背景下,研究睡眠障碍和AD病理之间的关系.
- 确定APOEε4如何影响睡眠剥夺对粉样蛋白和蛋白病理的影响.
主要方法:
- 使用一种表达人类APOE3或APOE4.4的转基因小鼠模型.
- 给小鼠进行睡眠剥夺,有或没有注射人类AD-tau.
- 评估了粉样蛋白和蛋白病理,微质聚类和缩神经炎.
主要成果:
- 在睡眠不足后,APOEε4加剧了粉样蛋白和蛋白病理.
- 睡眠不足的APOEε4小鼠显示微质聚类减少,神经损伤性神经炎增加.
- 在睡眠剥夺的APOEε4小鼠中,水素4水平和两极分化降低,损害了淋巴清除.
- APOEε4诱导的变化导致恢复期间睡眠行为发生变化,这表明有一个积极的反循环.
结论:
- APOEε4作为一种强大的调节器,在对睡眠障碍的反应中恶化AD病理.
- 淋巴功能受损和神经炎症变化有助于APOEε4载体睡眠剥夺的有害影响.
- 一个恶性循环存在,睡眠障碍加剧了AD病理,这反过来又进一步扰乱了睡眠,特别是在存在APOEε4.4的情况下.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.9K
相关概念视频
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
